Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti‐IL2 Receptor Monoclonal Antibodies?

Induction therapy with antilymphocyte biological agents is widely used after kidney transplantation, most commonly T lymphocyte‐depleting rabbit‐derived antithymocyte globulin (rATG) or an IL‐2 receptor antagonist (IL2RA). Early randomized trials showed that rATG or IL2RA induction reduces early acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellemans, R., Bosmans, J.‐L., Abramowicz, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215533/
https://www.ncbi.nlm.nih.gov/pubmed/27223882
http://dx.doi.org/10.1111/ajt.13884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215533/
https://www.ncbi.nlm.nih.gov/pubmed/27223882
http://dx.doi.org/10.1111/ajt.13884

Ejemplares similares